• News


Home>NEWS & MEDIA>News

Daewoong, signs contract with Boehringer Ingelheim Korea
Day : 2010-03-16

- 7 OTC Products in Boehringer Ingelheim Korea

- Expect to generate an incredible level of synergy in sales and marketing infra

Daewoong Co. Ltd signed a contract with Boehringer Ingelheim Korea in order to insure cooperation in their businesses on the 15th. Both companies, on this day, had a ceremony at Daewoong’s headquarters in Samsung-Dong. Daewoong CEO Lee Jong-Wook, vice CEO Kim Ji-Hyoung, Boehringer Ingelheim Korea’s CEO Guenter Reinke, vice CEO Adward joined together and shared their views on cooperation and marketing strategies.

As a result of this contract, Daewoong will be in charge of all seven of Boehringer Ingelheim Korea’s products locally, while Boehringer Ingelheim Korea leads the charge on marketing strategies. The products are, Dulcolax, Dulcolax balance, Buscopan, Mucopect, Mucoangin, Antistax, Pharmaton.
Especially Dulcolax leads the world market on constipation medicine, and as a symbol of approval from the FDA regarding safety and potency, has received the Category I honor. Furthermore, worldwide pain reliever Buscopan, efficient cough and mucus medicine Mucopect, are also included on the list, pushing for a win-win situation for both corporations.

At the ceremony, Boehringer Ingelheim Korea’s CEO Guenter Reinke stated “It is hopeful that we get the chance to work with a local corporation with vision” and also, “We hope that this contract will act as a momentum for both corporations’ development.”

Daewoong’s CEO Lee Jong-Wook said, “The worldwide Boehringer Ingelheim Korea and the local company that possesses the largest infrastructure working together will bear a synergy effect, and will be a win-win situation for both companies.”

Prev A new type of medicine for prostatic hypertrophy ‘OD Tablet’ launched
Next Daewoong Pharmaceutical Co. Ltd., introduced MIV-210, global new medicine for Hepatitis B